What's in Qin Ning's pipeline?

Qin Ning has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Qin Ning's portfolio?

No competitive overlap detected.

Subscribe to /feed/company/qin-ning.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Qin Ning pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Drug	Generic	Phase	Class	Target	Area	First approval
HBV vaccine	HBV vaccine	marketed
Granulocyte Macrophage Colony Stimulating Factor	Granulocyte Macrophage Colony Stimulating Factor	marketed

No therapeutic area data.

No regulatory actions in the last 90 days for this portfolio.

No PDUFA dates in the next 180 days for this portfolio.

No upcoming patent expiries for this portfolio.

No competitive overlap data.

Every new pipeline event for Qin Ning:

Drug Landscape (2026). Qin Ning — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/qin-ning. Accessed 2026-05-16.